[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-remission\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-remission":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,90,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100580234","comparison-of-30-day-morbidity-and-mortality-in-cancer-patients-based-on-emergency-department-location-100580234",false,"NCT06834646","Comparison of 30-day Morbidity and Mortality in Cancer Patients Based on Emergency Department Location","Comparison of 30-day Morbidity and Mortality in Cancer Patients Based on Emergency Department Location: Referring Oncology Hospital vs Other Hospitals.","COVER","Inclusion Criteria:\n\nPatients aged 18 or over admitted to an emergency department with cancer that has been active or in remission for less than a year.\n\nExclusion Criteria:\n\n\\- Opposition to participate in the study","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","Patients being followed for cancer account for 2.8% of emergency admissions in France. An acute episode that triggers a visit to the emergency department may be related to the progression of the disease, or to complications of treatment. The management of these patients is often complex and requires a degree of expertise. Emergency departments specialising in the management of cancer complications have been set up, and now deal exclusively with patients treated at their centres. However, for geographical or logistical reasons, patients with cancer are likely to consult a non-specialist emergency department and\u002For one located outside the cancer care centre. In this case, the emergency doctor may not have access to the oncology file, and care in the emergency department and downstream services may be sub-optimal. Studies have shown a positive impact on the quality of care and prognosis of patients thanks to the cancer centre's expertise. However, the effect of the centre on a cancer patient who visits the emergency department has never been studied. This is particularly true if the emergency department where the patient is seen is located in the cancer follow-up centre.\n\nThe primary objective of the COVER study is to investigate the impact of the location of the emergency department where the patient is seen for their prognosis.",[25,26],"Cancer","Cancer Remission",[28,25,29,30],"Emergency Department","Mortality","morbidity and mortality in Cancer","RECRUITING","2026-01-16",{"date":34,"type":35},"2026-01-20","ACTUAL",{"date":37,"type":35},"2025-04-12",{"date":39,"type":21},"2026-09",{"name":41,"class":42},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":54,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":69,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":43},"100616933","long-term-evaluation-of-fertility-preservation-options-in-women-in-cancer-remission-or-haematological-pathology-100616933","NCT07312058","Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematological Pathology","FERT-ISSUES","Inclusion Criteria:\n\n* Women\n* Aged between 18 and 47 years\n* Diagnosed with cancer or hematological disorders requiring potentially gonadotoxic treatment\n* Having undergone a medical fertility preservation consultation\n* Followed at Amiens Picardie University Hospital (CHU Amiens Picardie) in the department of Reproductive Medicine\n* Currently in remission\n* Having expressed non-opposition to participation in the study\n\nExclusion Criteria:\n\n* Absence of remission\n* Patients deprived of liberty by administrative or judicial decision, or placed under legal protection (guardianship or curators)\n* Decline to participate in the study","47 Years",{"count":53,"type":21},102,"1 Day","Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity.\n\nWomen of reproductive age are commonly offered fertility preservation (FP) before starting their treatment.\n\nHowever, few studies have analyzed the long-term reproductive outcomes of these interventions, nor how patients ultimately use or do not use the FP options once in remission.\n\nThis project aims to better understand the effectiveness, utilization, and psychological impacts of these strategies.\n\nThis work is part of an effort to understand and evaluate fertility preservation practices implemented for women of reproductive age undergoing cancer treatment at the Amiens-Picardie University Hospital (CHU).\n\nIts objective is to document patient pathways, clinical decisions, techniques employed, and reproductive outcomes observed after remission, in order to identify potential areas for improvement in the support and follow-up of these patients, thereby enhancing the overall quality and coordination of care.\n\nThis work is conducted alongside the development of a fertility observatory at the Department of Medicine and Reproductive Biology, CHU Amiens-Picardie.",[57,26,58,59,60,61,62,63,64,65,66,67,68],"Fertility Preservation","Reproductive Outcomes","Reproductive Health","Oncology","Fertility Counseling","Assisted Reproductive Technology","Psychological Impact","Fertility Observatory","Patient Follow-up","Female Cancer Survivors","Fertility Preservation Techniques","Live Birth Rate",[70,71,72,73,60,74,75,76,77,78,79,80,81],"Fertility preservation","Cancer remission","Reproductive outcomes","Reproductive health","Fertility counseling","Assisted reproductive technology","Psychological impact","Fertility observatory","Patient follow-up","Female cancer survivors","Fertility preservation techniques","Live birth rate","2026-01-15",{"date":32,"type":35},{"date":85,"type":21},"2025-12-17",{"date":87,"type":21},"2027-01",{"name":89,"class":42},"Centre Hospitalier Universitaire, Amiens",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":43},"100444931","relationships-between-physical-activity-and-different-measures-of-fatigue-in-cancer-survivors-100444931","NCT05073848","Relationships Between Physical Activity and Different Measures of Fatigue in Cancer Survivors","Inclusion Criteria:\n\n* Be an active participant in the BfitBwell Cancer Exercise Program\n* Criteria for this program include:\n* Adult (\\>= 18 years old)\n* Being a patient seen at the University of Colorado Cancer Center\n* Currently receiving cancer therapy or be within 6 months of completing cancer therapy\n* Have a signed physician clearance form to participate in an exercise program\n* Have a smartphone (necessary for the EMA assessments)\n* A score of 48 or less on the FACIT-Fatigue (completed during the initial BfitBwell Program assessment)\n* The minimally important difference of the FACIT-Fatigue is 3 points, suggesting that a score of at most 48 indicates the presence of CRF and allows for meaningful change in both directions.\n\nExclusion Criteria:\n\n* None",{"count":97,"type":21},150,"This is an investigation of possible relationships between daily physical activity (PA) and different measurements of fatigue in cancer survivors participating in a cancer exercise program.",[26],"2025-07-02",{"date":102,"type":35},"2025-07-08",{"date":104,"type":35},"2021-10-20",{"date":106,"type":21},"2026-06-01",{"name":108,"class":42},"University of Colorado, Denver",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":133,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":156},"100551613","phase-1-prevention-of-gvhd-in-participants-with-hematological-malignancies-undergoing-hematopoietic-stem-cell-transplant-hsct-100551613","NCT06462365","Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)","Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)","Inclusion Criteria:\n\n1. Subjects with one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (B- or T-ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), or Chronic myelomonocytic leukemia (CMML)\n2. Males and Females Age ≥ 18 years.\n3. Weight of ≥ 35 Kg.\n4. Karnofsky performance status ≥ 70 %.\n5. Available mismatched related (haploidentical) or unrelated donors for peripheral blood stem cell (PBSC) donation.\n6. Subjects must otherwise fulfill institutional criteria for eligibility to undergo allogeneic stem cell transplantation.\n7. Absence of uncontrolled bacterial, viral or fungal infection at time of enrollment.\n8. Have adequate organ function.\n9. Subjects \\> 65-year-old receiving MAC conditioning will only be eligible if they have a HSCT-comorbidity index score \\\u003C 5.\n10. Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits.\n\nExclusion Criteria:\n\n1. Prior allogeneic bone marrow, peripheral blood, or cord blood HSCT.\n2. Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction.\n3. HIV positive.\n4. Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.\n5. Positive hepatitis-C antibody with positive Recombinant Immunoblot Assay (RIBA) or PCR unless the subject has received curative anti-viral treatment and confirmed negative viral load by PCR.\n6. Received another investigational agent for treatment of disease understudy within 28 days (or 5 half-lives, whichever is shorter) of conditioning and\u002For have not recovered from treatment related toxicities.\n7. Subjects with a previous history of Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS) who are not good candidates for treatment with sirolimus.\n8. Subjects that are pregnant, breast feeding or aim to become pregnant during the study period. (Subjects must agree to use a highly effective method of contraception).\n9. Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results.",{"count":117,"type":21},36,"INTERVENTIONAL",[120],"PHASE1","The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.",[123,124,125,126,127,128,129,130,131,132,26],"Hematologic Malignancy","GvHD","GVHD,Acute","GVHD, Chronic","Hematopoietic Stem Cell Transplant","Acute Lymphoblastic Leukemia, Adult B-Cell","Acute Lymphoblastic Leukemia, Adult T-Cell","Acute Myeloid Leukemia in Remission","Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia, in Remission",[134,135,136,137,138,139,140,141,142,143,144,145],"AML","CMML","Stem Cell Transplant","B-ALL","T-ALL","Acute GvHD","Graft versus Host Disease","Chronic GvHD","MDS","Cellular Therapy","Autoimmune","T regulatory cells","2025-04-10",{"date":148,"type":35},"2025-04-15",{"date":150,"type":35},"2024-04-08",{"date":152,"type":21},"2027-04-15",{"name":154,"class":155},"Tr1X, Inc.","INDUSTRY",5]